Solid Biosciences Inc. (SLDB) Current Ratio
- Current ratio · latest quarter: Value 13.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 13.82× | Current assets / current liabilities. $395.11M ÷ $28.58M ≈ 13.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 395.11M USD | Assets, Current |
| Current obligations | 28.58M USD | Liabilities, Current |
| Cash and equivalents | 159.39M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 218.28M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.36M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $395.11M | $28.58M | $159.39M | $218.28M | (m) | (m) | $4.36M | (m) | 13.82× |
| 2026-03-31 | $396.79M | $30.28M | $297.10M | $83.58M | (m) | (m) | $5.56M | (m) | 13.10× |
| 2025-12-31 | $205.46M | $33.47M | $59.90M | $127.95M | (m) | (m) | $3.22M | (m) | 6.14× |
| 2025-09-30 | $244.85M | $36.34M | $61.36M | $174.78M | (m) | (m) | $8.43M | (m) | 6.74× |
| 2025-06-30 | $278.64M | $29.85M | $138.93M | $129.18M | (m) | (m) | $4.70M | (m) | 9.34× |
| 2025-03-31 | $313.41M | $28.78M | $210.63M | $96.29M | (m) | (m) | $6.44M | (m) | 10.89× |
| 2024-12-31 | $157.30M | $30.26M | $80.23M | $68.69M | (m) | (m) | $4.24M | (m) | 5.20× |
| 2024-09-30 | $179.49M | $22.85M | $64.39M | $106.72M | (m) | (m) | $3.46M | (m) | 7.85× |
| 2024-06-30 | $197.61M | $14.69M | $95.85M | $94.41M | (m) | (m) | $2.52M | (m) | 13.45× |
| 2024-03-31 | $214.19M | $14.34M | $117.57M | $88.49M | (m) | (m) | $1.73M | (m) | 14.94× |
| 2023-12-31 | $129.73M | $14.52M | $74.02M | $49.63M | (m) | (m) | $2.03M | (m) | 8.94× |
| 2023-09-30 | $148.35M | $15.82M | $49.04M | $93.85M | (m) | (m) | $1.90M | (m) | 9.38× |
| 2023-06-30 | $167.47M | $15.87M | $91.57M | $68.62M | (m) | (m) | $2.97M | (m) | 10.56× |
| 2023-03-31 | $190.60M | $20.29M | $164.65M | $20.86M | (m) | (m) | $5.59M | (m) | 9.39× |
| 2022-12-31 | $219.64M | $22.51M | $155.38M | $58.34M | (m) | (m) | $3.24M | (m) | 9.76× |
| 2022-09-30 | $147.51M | $16.93M | $48.79M | $93.37M | (m) | (m) | $5.15M | (m) | 8.72× |
| 2022-06-30 | $170.44M | $21.72M | $54.31M | $108.57M | (m) | (m) | $5.11M | (m) | 7.85× |
| 2022-03-31 | $198.61M | $21.74M | $129.71M | $50.34M | (m) | (m) | $4.76M | (m) | 9.13× |
| 2021-12-31 | $222.61M | $23.60M | $119.14M | $88.64M | (m) | (m) | $4.46M | (m) | 9.43× |
| 2021-09-30 | $238.81M | $22.54M | $109.68M | $120.08M | (m) | (m) | $4.15M | (m) | 10.59× |
| 2021-06-30 | $255.08M | $22.55M | $200.61M | $48.35M | (m) | (m) | $3.00M | (m) | 11.31× |
| 2021-03-31 | $274.30M | $22.83M | $268.50M | (m) | (m) | (m) | $3.19M | (m) | 12.02× |
| 2020-12-31 | $158.90M | $24.48M | $154.74M | (m) | (m) | (m) | $3.27M | (m) | 6.49× |
| 2020-09-30 | $27.16M | $14.77M | $24.80M | (m) | (m) | (m) | $4.08M | (m) | 1.84× |
| 2020-06-30 | $43.53M | $13.17M | $40.44M | (m) | (m) | (m) | $2.79M | (m) | 3.31× |
| 2020-03-31 | $57.90M | $12.88M | $53.19M | $400.00K | (m) | (m) | $2.38M | (m) | 4.50× |
| 2019-12-31 | $86.30M | $18.28M | $76.04M | $7.48M | (m) | (m) | $7.12M | (m) | 4.72× |
| 2019-09-30 | $113.49M | $16.75M | $94.72M | $10.94M | (m) | (m) | $3.21M | (m) | 6.78× |
| 2019-06-30 | $78.32M | $13.67M | $51.84M | $15.55M | (m) | (m) | $5.60M | (m) | 5.73× |
| 2019-03-31 | $101.79M | $14.57M | $53.99M | $40.75M | (m) | (m) | $5.35M | (m) | 6.99× |
| 2018-12-31 | $128.64M | $12.48M | $86.37M | $36.10M | (m) | (m) | $3.69M | (m) | 10.31× |
| 2018-09-30 | $148.43M | $10.64M | $129.14M | $16.23M | (m) | (m) | $4.80M | (m) | 13.95× |
| 2018-06-30 | $164.47M | $8.68M | $145.82M | $16.93M | (m) | (m) | $3.74M | (m) | 18.95× |
| 2018-03-31 | $184.38M | $9.93M | $164.77M | $17.61M | (m) | (m) | $5.83M | (m) | 18.57× |
| 2017-12-31 | $70.66M | $11.27M | $52.08M | $17.01M | (m) | (m) | $5.07M | (m) | 6.27× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |